Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: A relative survival analysis from Finland
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Reports on the prognosis of familial breast cancer patients have been contradictory. True differences in survival, if they exist, would have important implications for genetic counselling and in treatment of hereditary breast cancer. We assessed the survival rates of 359 familial breast cancer patients (32 patients from BRCA1-positive families, 43 patients from BRCA2-positive families and 284 patients from BRCA1/2-negative breast cancer families) and compared them with those of all other breast cancer patients diagnosed in Finland from 1953 to 1995 (n = 59,517). Cumulative relative survival rates (RSR) were calculated by dividing the observed survival rates by the expected ones. The expected survival rates were derived from the sex, age and calendar year specific life-tables of the general population in Finland. Regression model was used to calculate relative excess risk of death (RR) and to adjust for confounding factors. The overall 5-year RSR of the patients in the BRCA1 families, BRCA2 families, non-BRCA1/2 families and among sporadic cases was 67%, 77%, 86% and 78%, respectively. However, we found no significant differences in the RR adjusted for age, stage and year of diagnosis between the different familial patient groups or the general breast cancer population. In the BRCA1 families the RR tended to be higher [RR 1.30, 95% confidence interval (CI) 0.63--2.70] and in the BRCA2 families lower (RR 0.78, 95% CI 0.39--1.57) than among the general breast cancer patient population. The RR among patients in the non-BRCA1/2 families did not differ from that of the general patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
Jóhannsson, O. T., Ranstam, J., Borg, A., & Olsson, H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.397 · Cited by 254 · cited 3×
“1953–1982 8 (25) 53 16–90 11 (26) 49 17–81 42 (15) 52 34–69 10,464 (18) 56 55–57 1983–1995 5 (16) 69 18–119 10 (23) 83 52–114 49 (17) 91 76–106 9,308 (16) 75 74–76 Period of diagnosis and age 1953–1982 0–49 years 12 (38) 68 40–96 10 (23) 62 30–94 44 (15) 73 59–87 8,470 (14) 71 70–72 501 years 9 (28) 53 15–92 11 (26) 6…”
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome
Foulkes, W. D., Chappuis, P. O., Wong, N., Brunet, J.-S., Vesprini, D., Rozen, F., Yuan, Z. Q., Pollak, M. N., Kuperstein, G., Narod, S. A., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008340723974 · Cited by 86
Survival and tumor characteristics of German hereditary breast cancer patients
Hamann, U., & Sinn, H.-P. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006350518190 · Cited by 48
Prognosis and clinical presentation of BRCA2-associated breast cancer
Loman, N., Johannsson, O., Bendahl, P.-O., Dahl, N., Einbeigi, Z., Gerdes, A.-M., Borg, Å., & Olsson, H. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00098-8 · Cited by 46 · cited 2×
“0–49 years 7 (22) 59 20–97 12 (28) 66 37–96 32 (11) 66 48–84 6,106 (10) 64 63–65 501 years 6 (19) 59 11–107 9 (21) 59 18–99 59 (21) 76 60–92 13,666 (23) 65 64–66 Stage and period of diagnosis Localized 1953–1982 11 (34) 79 50–108 7 (16) 97 67–127 77 (27) 100 91–110 14,390 (24) 89 89–90 1983–1995 5 (16) 73 24–122 10 (2…”
Cited by
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967
An overview of prognostic factors for long-term survivors of breast cancer
Soerjomataram, I., Louwman, M. W. J., Ribot, J. G., Roukema, J. A., & Coebergh, J. W. W. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9556-1 · Cited by 513
Katipamula, R., Degnim, A. C., Hoskin, T., Boughey, J. C., Loprinzi, C., Grant, C. S., Brandt, K. R., Pruthi, S., Chute, C. G., Olson, J. E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.4225 · Cited by 373
Clinical Outcomes of Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations
Rennert, G., Bisland-Naggan, S., Barnett-Griness, O., Bar-Joseph, N., Zhang, S., Rennert, H. S., & Narod, S. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070608 · Cited by 302
The Genetic Epidemiology of Breast Cancer Genes
Thompson, D., & Easton, D. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000048770.90334.3b · Cited by 257
Metadata
- Authors
- Eerola, H., Vahteristo, P., Sarantaus, L., Kyyr�nen, P., Pyrh�nen, S., Blomqvist, C., Pukkala, E., Nevanlinna, H., & Sankila, R.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2001
- Volume
- 93
- Issue
- 3
- Pages
- 368-372
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2033149008
- Cited by
- 65
- References
- 5
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: A relative survival analysis from Finland. https://app.cochat.ai/papers/10.1002/ijc.1341
- The paper
- Eerola, H., Vahteristo, P., Sarantaus, L., Kyyr�nen, P., Pyrh�nen, S., Blomqvist, C., Pukkala, E., Nevanlinna, H., & Sankila, R. (2001). Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: A relative survival analysis from Finland. International Journal of Cancer. https://doi.org/10.1002/ijc.1341
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.